Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries

Sung, 2021, Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Ferlay, 2020 1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group, BMJ, 311, 899, 10.1136/bmj.311.7010.899 2008, Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials, J Clin Oncol, 26, 4617, 10.1200/JCO.2008.17.7162 Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Zhou, 2015, BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer, J Clin Oncol, 33, 2197, 10.1200/JCO.2014.59.4424 Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375 The ESMO Guidelines Committee, Clinical Practice Living Guidelines – Metastatic Non-Small-Cell Lung Cancer | ESMO. 2020, European Society for Medical Oncology. Planchard, 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, iv192, 10.1093/annonc/mdy275 Novello, 2016, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 27, v1, 10.1093/annonc/mdw326 Ramalingam, 2019, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N Engl J Med, 382, 41, 10.1056/NEJMoa1913662 Maemondo, 2020, NEJ026: final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations, J Clin Oncol, 38 Mok, 2020, Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study, Ann Oncol, 31, 1056, 10.1016/j.annonc.2020.04.478 Pacheco, 2019, Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer, J Thorac Oncol, 14, 691, 10.1016/j.jtho.2018.12.014 World Health Organization, 2013 Bray, 2021 Tan, 2020, Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis, Lung Cancer, 139, 207, 10.1016/j.lungcan.2019.11.022 Aguilar, 2018, Treatment patterns by EGFR mutation status in non-small cell lung cancer patients in the USA: a retrospective database analysis, Adv Ther, 35, 1905, 10.1007/s12325-018-0811-0 Berry, 2013, Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer, J Thorac Oncol, 8, 744, 10.1097/JTO.0b013e31828916aa Darling, 2014, Quality indicators for non-small cell lung cancer operations with use of a modified Delphi consensus process, Ann Thorac Surg, 98, 183, 10.1016/j.athoracsur.2014.03.001 Driessen, 2018, Patterns of treatment and survival among older patients with stage III non-small cell lung cancer, Lung Cancer, 116, 55, 10.1016/j.lungcan.2017.12.013 Enewold, 2016, Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States, PLoS One, 11, 10.1371/journal.pone.0156728 Furqan, 2018, Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis, J Thorac Dis, 10, 5850, 10.21037/jtd.2018.09.141 Jakobsen, 2013, Nationwide quality improvement in lung cancer care: the role of the Danish Lung Cancer Group and Registry, J Thorac Oncol, 8, 1238, 10.1097/JTO.0b013e3182a4070f Kapadia, 2017, Patterns of treatment and outcomes for definitive therapy of early stage non-small cell lung cancer, Ann Thorac Surg, 104, 1881, 10.1016/j.athoracsur.2017.06.065 Khare, 2016, Identification of performance indicators across a network of clinical cancer programs, Curr Oncol, 23, 81, 10.3747/co.23.2789 Nilsson, 2017, The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study, Acta Oncol, 56, 949, 10.1080/0284186X.2017.1324213 Sandelin, 2015, Patients with non-small cell lung cancer analyzed for EGFR: adherence to guidelines, prevalence and outcome, Anticancer Res, 35, 3979 2017 Shen, 2017, Utilization patterns and trends in epidermal growth factor receptor (EGFR) mutation testing among patients with newly diagnosed metastatic lung cancer, Clin Lung Cancer, 18, e233, 10.1016/j.cllc.2016.11.002 Sher, 2014, Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution, Int J Radiat Oncol Biol Phys, 89, 303, 10.1016/j.ijrobp.2014.01.033 Skov, 2015, The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population, APMIS, 123, 108, 10.1111/apm.12328 Stirling, 2014, The Victorian Lung Cancer Registry Pilot: improving the quality of lung cancer care through the use of a disease quality registry, Lung, 192, 749, 10.1007/s00408-014-9603-8 Tsai, 2018, Impact of targeted therapy on the quality of end-of-life care for patients with non-small-cell lung cancer: a population-based study in Taiwan, J Pain Symptom Manage, 55, 798, 10.1016/j.jpainsymman.2017.10.009 Vrijens, 2016 Wang, 2017, Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China, BMC Cancer, 17, 603, 10.1186/s12885-017-3602-0 Wu, 2011, Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study, Cancer, 117, 618, 10.1002/cncr.25616 Harris, 2019, The REDCap consortium: building an international community of software platform partners, J Biomed Inform, 95, 10.1016/j.jbi.2019.103208 Bray, 2014 Ferlay, 2005 2016, 272 Sankaranarayanan, 2014, Managing the changing burden of cancer in Asia, BMC Med, 12, 3, 10.1186/1741-7015-12-3 2019, Organisation for Economic Co-operation and Development, 219 He, 2022, Real-world patient characteristics, treatment patterns, and mutation testing patterns among US patients with advanced non-small cell lung cancer Harboring EGFR mutations, Adv Ther, 39, 3347, 10.1007/s12325-022-02189-z Kerr, 2021, The evolving landscape of biomarker testing for non-small cell lung cancer in Europe, Lung Cancer, 154, 161, 10.1016/j.lungcan.2021.02.026 Kimman, 2015, Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries, BMC Med, 13, 190, 10.1186/s12916-015-0433-1 Reungwetwattana, 2020, Lung cancer in Thailand, J Thorac Oncol, 15, 1714, 10.1016/j.jtho.2020.04.024 Ramadani, 2018, Inequities of access, utilization and clinical outcome of lung cancer in Indonesia, J Global Oncol, 4 Rajadurai, 2020, Lung cancer in Malaysia, J Thorac Oncol, 15, 317, 10.1016/j.jtho.2019.10.021 Ang, 2021, Lung cancer in Singapore, J Thorac Oncol, 16, 906, 10.1016/j.jtho.2020.11.020 Parkin, 2008, The role of cancer registries in cancer control, Int J Clin Oncol, 13, 102, 10.1007/s10147-008-0762-6 Boyle, 1991 Soerjomataram, 2021, Impact of the COVID-19 pandemic on population-based cancer registry, Int J Cancer, 150, 273, 10.1002/ijc.33792 Kruk, 2018, High-quality health systems in the Sustainable Development Goals era: time for a revolution, Lancet Global Health, 6, e1196, 10.1016/S2214-109X(18)30386-3 Cortes, 2020, Enhancing global access to cancer medicines, CA Cancer J Clin, 70, 105, 10.3322/caac.21597 Cherny, 2017, ESMO-Magnitude of Clinical Benefit Scale version 1.1, Ann Oncol, 28, 2340, 10.1093/annonc/mdx310 Eniu, 2019, Cancer medicines in Asia and Asia-Pacific: what is available, and is it effective enough?, ESMO Open, 4, 10.1136/esmoopen-2018-000483 Gatellier, 2020, An Asian body to tackle cancers in Asia—The Asian National Cancer Centers Alliance, Asian Pac J Cancer Prev, 21, 1207, 10.31557/APJCP.2020.21.5.1207 Moore, 2014, Cancer control programs in East Asia: evidence from the international literature, J Prev Med Public Health, 47, 183, 10.3961/jpmph.2014.47.4.183 Smeltzer, 2020, The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer, J Thorac Oncol, 15, 1434, 10.1016/j.jtho.2020.05.002